Content uploaded by Nancy Elizabeth Wight
Author content
All content in this area was uploaded by Nancy Elizabeth Wight on Feb 05, 2015
Content may be subject to copyright.
ABM Protocol
ABM Clinical Protocol #1:
Guidelines for Blood Glucose Monitoring
and Treatment of Hypoglycemia in Term
and Late-Preterm Neonates, Revised 2014
Nancy Wight,
1,2
Kathleen A. Marinelli,
3,4
and The Academy of Breastfeeding Medicine
A central goal of The Academy of Breastfeeding Medicine is the development of clinical protocols for managing
common medical problems that may impact breastfeeding success. These protocols serve only as guidelines for the
care of breastfeeding mothers and infants and do not delineate an exclusive course of treatment or serve as standards
of medical care. Variations in treatment may be appropriate according to the needs of an individual patient.
Purpose
T
o provide guidance in the first hours/days of life to:
Prevent clinically significant hypoglycemia in infants
Appropriately monitor blood glucose levels in at-risk
term and late-preterm infants
Manage documented hypoglycemia in infants
Establish and preserve maternal milk supply during
medically necessary supplementation for hypoglycemia
or during separation of mother and baby
Background
Physiology
The term ‘‘hypoglycemia’’ refers to a low blood glucose
concentration. Clinically significant neonatal hypoglycemia
reflects an imbalance between the supply and utilization of
glucose and alternative fuels and may result from several dis-
turbed regulatory mechanisms.
1
Transient hypoglycemia in the
first hours after birth is common, occurring in almost all mam-
malian newborns. In healthy, term human infants, even if early
enteral feeding is withheld, this phenomenon is self-limited,
without clinical signs, and considered to be part of adaptation to
postnatallife,asglucoselevelsspontaneouslyrisewithinthefirst
24 hours after birth (for some, it is even longer but still physio-
logical).
2–6
Mostneonates compensate forthis‘‘physiological’’
low blood glucose with endogenous fuel production through
gluconeogenesis, glycogenolysis, and ketogenesis, collectively
called‘‘counter-regulation.’’Evenin thosesituationswherelow
blood glucose concentrations do develop secondary to pro-
longed intervals (> 8 hours) between breastfeeding, a marked
ketogenic response occurs. The enhanced capability of the
neonatal brain to utilize ketonebodiesprovides glucose-sparing
fuel to the brain, protecting neurological function.
3,7–9
The
compensatory provision of alternate fuels constitutes a normal
adaptive response to transiently low nutrient intake during the
establishment of breastfeeding,
3,10
resulting in most breastfed
infants tolerating lower plasma glucose levels without any sig-
nificant clinical manifestations or sequelae.
10
No studies have shown that treating transiently low blood
glucose levels results in better short-term or long-term outcomes
compared with no treatment, and in fact there is no evidence at
all that hypoglycemic infants with no clinical signs benefit from
treatment.
11,12
Increases in neurodevelopmental abnormalities
have been found in infants who have hypoglycemia associated
with abnormal clinical signs, especially those with severe, per-
sistent hyperinsulinemic hypoglycemia.
11–16
Rozance and
Hay
17
have delineated the conditions that should be present
before consideri ng that long-term neurologic impairment might
be related to neonatal hypoglycemia. Transient, single, brief
periods of hypoglycemia are unlikely to cause permanent
neurologic damage.
18–21
Therefore, the monitoring of blood
glucose concentrations in healthy, term, appropriately grown
neonates is unnecessary and potentially harmful to parental well-
being and the successful establishment of breastfeeding.
18–23
Definition of hypoglycemia
The definition of hypoglycemia in the newborn infant
has remained controversial because of a lack of significant
1
San Diego Neonatology, Inc., San Diego, California.
2
Sharp HealthCare Lactation Services, Sharp Mary Birch Hospital for Women and Newborns, San Diego, California.
3
Division of Neonatology and The Connecticut Human Milk Research Center, Connecticut Children’s Medical Center, Hartford,
Connecticut.
4
University of Connecticut School of Medicine, Farmington, Connecticut.
BREASTFEEDING MEDICINE
Volume 9, Number 4, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/bfm.2014.9986
173
correlation among plasma glucose concentration, clinical
signs, and long-term sequelae.
10,24,25
An expert panel con-
vened in 2008 by the U.S. National Institutes of Health
concluded that there has been no substantial evidence-based
progress in defining what constitutes clinically important
neonatal hypoglycemia, particularly regarding how it relates
to brain injury.
26
Multiple reviews have concluded that there
is no specific plasma or blood glucose concentration or du-
ration of low blood glucose level that can be linked to either
clinical signs or permanent neurologic injury.
17,25,27
In ad-
dition, blood glucose test results vary enormously with the
source of the blood sample, the assay method, and whether
whole blood, plasma, or serum glucose concentration is de-
termined. Plasma or serum glucose concentrations are 10–15%
higher than in whole blood.
28,29
Breastfed, formula-fed, and mixed-fed infants follow the
samepatternofglucosevalues,withaninitialfallinglucoselevel
overthe first 2 hours of life,followed by a gradual riseinglucose
level over the next 96 hours, whether fed or not.
2,5,6
Artificially
fedinfantstendtohaveslightlyhigherlevelsofglucoseandlower
levels of ketone bodies than breastfed infants.
3,5,18,30–32
The incidence of ‘‘hypoglycemia’’ varies with th e d efi-
nition.
33,34
Many authors have suggested numeric defini-
tions of hypoglycemia, usually between 30 and 50 mg/dL
(1.7–2.8 mmol/L) and varying by postnatal age.
2,5,18,24,26,33,35–38
There i s no scientific justification for the value of < 47 mg/dL
(2.6 mmol/L) that has been adopted by some clinicians.
10,25–27,39
Cornblath et al.
10
summarized the problem as follows:
Significant hypoglycemia is not and cannot be defined as a
single number that can be applied universally to every indi-
vidual patient. Rather, it is characterized by a value(s) that is
unique to each individual and varies with both their state of
physiologic maturity and the influence of pathology
A meta-analysis of studies published from 1986 to 1994
looked at low plasma glucose thresholds in term healthy
newborns who were mostly mixed fed (breastfed and for-
mula-fed) or formula-fed. It presented statistical ranges of
low thresholds for plasma glucose level based on hours after
birth in healthy term infants (Table 1).
40
The authors spe-
cifically noted that given the known lower plasma glu-
cose levels in healthy term breastfed infants as compared
with formula-fed infants, the low thresholds for exclusively
breastfed infants might even be lower. Table 1 gives rec-
ommendations for this timed threshold approach.
This information is translated into guidelines for clinical in-
tervention by the operational treatment guidance of Cornblath
et al.
10
As they stated, an operational threshold is that concen-
tration of plasma or whole blood glucose at which clinicians
should consider intervention, based on the evidence currently
available in the literature (Table 2). It needs to be underscored
that the therapeutic objective (45 mg/dL [2.5 mmol/L]) is dif-
ferentfromthe operationalthreshold forintervention(36 mg/dL
[2.0 mmol/L]), which is different from the population low
thresholds in normal babies with no clinical signs or risk
factors w ho do not need to be treated (Table 1). The higher
therapeutic goal was c hosen to include a significant margin of
safety in the absence of data evaluating the correlation be-
tween glucose levels in this range and long-term outcome in
full-term infants.
10
Given this information, it is clear that routine monitoring
of blood glucose in healthy term infants is not only unnec-
essary, but is instead potentially harmful to the establish-
ment of a healthy mother–infant relationship and successful
breastfeeding patterns.
1,20,22,23,41,42
This recommendation
has been supported by the World Health Organization,
18
the
American Academy of Pediatrics,
1,41
the U.S. National In-
stitutes of Health,
26
and the National Childbirth Trust of the
United Kingdom.
43
These organizations all conclude that (1)
early and exclusive breastfeeding is safe to meet the nutri-
tional needs of healthy term infants and that (2) healthy term
Table 1. Population Low Thresholds:
Plasma Glucose Level
40
Hour(s) after
birth
£ 5
th
percentile plasma
glucose level
1–2 (nadir) 28 mg/dL (1.6 mmol/L)
3–47 40 mg/dL (2.2/mmol/L)
48–72 48 mg/dL (2.7 mmol/L)
Table 2. Operational Thresholds for Treatment of Plasma Glucose Levels
10
Infant Plan/PGL Treatment
Infant with clinical
signs
If < 45 mg/dL
(2.5 mmol/L)
Clinical interventions to increase
blood glucose concentration
Infants with
risk factors
a
Initiate glucose monitoring as
soon as possible after birth,
within 2–3 hours after birth
and before feeding, or at any
time there are abnormal signs.
If plasma glucose concentration
is < 36 mg/dL (2.0 mmol/L),
close surveillance should
be maintained. Intervention
is recommended if plasma
glucose remains below this level,
does not increase after a feed, or
if abnormal clinical signs develop.
Clinical interventions to increase blood glucose
concentration: at very low glucose concentration
(20–25 mg/dL, 1.1–1.4 mmol/L), intravenous
glucose infusion to raise plasma glucose levels
to > 45 mg/dL (2.5 mmol/L) is indicated.
PGL, plasma glucose level.
a
See Table 3.
174 ABM PROTOCOL
infants do not develop clinically significant hypoglycemia
simply as a result of a time-limited duration of underfeeding.
Testing methods
Bedside glucose reagent test strips are inexpensive and
practical but are not reliable, with significant variance from
true blood glucose levels, especially at low glucose concen-
trations.
22,38,44–46
Bedside glucose tests may be used for
screening, but laboratory levels sent STAT (immediate de-
termination, without delay) (e.g., glucose oxidase, hexoki-
nase, or dehydrogenase method) must confirm results before
a diagnosis of hypoglycemia can be made, especially in
infants with no clinical signs.
1,18,22
Other bedside rapid
measurement methods such as reflectance colorimetry and
electrode methods may be more accurate.
47–50
Continuous
subcutaneous glucose monitoring, as is used in diabetic pa-
tients, has been used experimentally in neonates with good
correlation with laboratory glucose values but is not currently
recommended for screening.
51,52
Risk factors for hypoglycemia
Neonates at increased risk for developing neonatal hypo-
glycemia should be routinely monitored for blood glucose
levels irrespective of the mode of feeding. At-risk neonates
fall into two main categories:
1. Excess utilization of glucose, which includes the hy-
perinsulinemic states
2. Inadequate production or substrate delivery
32,53,54
Infant risk factors for hypoglycemia are listed in
Table 3.
3,10,18,19,21,30,32,34,53–56
Clinical manifestations of hypoglycemia
The clinical manifestations of hypoglycemia are nonspe-
cific, occurring with various other neonatal problems. Even in
the presence of an arbitrary low glucose level, the physician
must assess the general status of the infant by observation and
physical examination to rule out other disease entities and
processes that may need additional laboratory evaluation and
treatment. Some common clinical signs are listed in Table 4.
A recent study found that of the 23 maternal/infant risk
factors and infant signs/symptoms studied, only jitteriness
and tachypnea were statistically significant at predicting low
blood glucose—not even maternal diabetes!
57
A diagnosis of
hypoglycemia also requires that signs abate after normogly-
cemia is restored (the exception being if brain injury has
already been sustained).
General Management Recommendations (Table 5)
Any approach to management needs to account for the
overall metabolic and physiologic status of the infant and
should not unnecessarily disrupt the mother–infant relation-
ship and breastfeeding.
1,21
Because severe, prolonged hy-
poglycemia with clinical signs may result in neurologic
injury,
11,14,15,58
immediate intervention is needed for infants
with clinical signs. Several authors have suggested algo-
rithms for screening and treatment.
1,17,26,27,59
(Quality of
evidence [levels of evidence I, II-1, II-2, II-3, and III] is based
on the U.S. Preventive Services Task Force Appendix A Task
Force Ratings
60
and is noted in parentheses.)
A. Initial management
Early and exclusive breastfeeding meets the nutritional
and metabolic needs of healthy, term newborn infants.
Healthy term infants do not develop clinically significant
hypoglycemia simply as a result of time-limited underfeed-
ing.
18,19,21
(III)
1. Healthy, appropriate weight for gestational age, term
infants should initiate breastfeeding within 30–60
minutes of life and continue breastfeeding on cue, with
Table 3. At-Risk Infants for Whom Routine
Monitoring of Blood Glucose Is Indicated
Small for gestational age: < 10
th
percentile for weight
commonly cited in the United States; < 2
nd
percentile
cited in the United Kingdom as above this considered
small normal
a
Babies with clinically evident wasting of fat and
muscle bulk
LGA: > 90
th
percentile for weight and macrosomic
appearance
b
Discordant twin: weight 10% < larger twin
All infants of diabetic mothers, especially if poorly
controlled
Low birth weight (< 2,500 g)
Prematurity (< 35 weeks, or late preterm infants with
clinical signs or extremely poor feeding)
Perinatal stress: severe acidosis or hypoxia-ischemia
Cold stress
Polycythemia (venous Hct > 70%)/hyperviscosity
Erythroblastosis fetalis
Beckwith–Wiedemann’s syndrome
Microphallus or midline defect
Suspected infection
Respiratory distress
Known or suspected inborn errors of metabolism or
endocrine disorders
Maternal drug treatment (e.g., terbutaline,
beta-blockers, oral hypoglycemics)
Infants displaying signs associated with hypoglycemia
(see Table 4)
a
As per Dr. Jane Hawdon (personal communication).
b
Unnecessary to screen all large for gestational age (LGA) babies.
Glucose monitoring is recommended for infants from maternal
populations who were unscreened for diabetes during the pregnancy
where LGA may represent undiagnosed and untreated maternal
diabetes.
Hct, hematorit.
Table 4. Clinical Manifestations of Possible
Hypoglycemia
Irritability, tremors, jitteriness
Exaggerated Moro reflex
High-pitched cry
Seizures or myoclonic jerks
Lethargy, listlessness, limpness, hypotonia
Coma
Cyanosis
Apnea or irregular breathing
Tachypnea
Hypothermia; temperature instability
Vasomotor instability
Poor suck or refusal to feed
ABM PROTOCOL 175
the recognition that that crying is a very late sign of
hunger.
41,61,62
(III)
2. Initiation and establishment of breastfeeding, and re-
duction of hypoglycemia risk, are facilitated by skin-
to-skin contact between the mother and her infant
immediately after birth for at least the first hour of life
and continuing as much as possible. Such practices
will maintain normal infant body temperature and re-
duce energy expenditure (thus enabling maintenance
of normal blood glucose) while stimulating suckling
and milk production.
31,41
(II-2, III)
3. Feedings should be frequent, at least 10–12 times per
24 hours in the first few days after birth.
41
(III)
However, it is not unusual for term infants to feed
immediately after birth and then sleep quite a long
time (up to 8–12 hours) before they become more
active and begin to suckle with increasing frequency.
They mount protective metabolic responses through-
out this time so it is not necessary to try to force-feed
them. However, an unusually, excessively drowsy
baby must undergo clinical evaluation.
4. Routine supplementation of healthy term infants with
water, glucose water, or formula is unnecessary and
may interfere with the establishment of normal
breastfeeding and normal metabolic compensatory
mechanisms.
3,30,41,43
(II-2, III)
B. Blood glucose screening
Glucose screening should be performed only on at-risk
infants and those with clinical signs compatible with hypo-
glycemia. Early breastfeeding is not precluded just because
the infant meets the criteria for glucose monitoring.
1. At-risk infants should be screened for hypoglycemia
with a frequency and duration related to the specific risk
factors of the individual infant.
1,19
(III) Monitoring
should begin no later than 2 hours of age for infants in
risk categories.
1
Hawdon
63
recommended blood glu-
cose monitoring should commence before the second
feeding (i.e., not so soon after birth that the physiologic
fall in blood glucose level causes confusion and over-
treatment). (III)
2. Monitoring should continue until acceptable, prefeed
levels are consistently obtained, meaning until the in-
fant has had at least two consecutive satisfactory mea-
surements.
63
A reasonable (although arbitrary) goal is to
maintain plasma glucose concentrations between 40 and
50 mg/dL (between 2.2and 2.8 mmol/L)
1
or > 45 mg/dL
(2.5 mmol/L).
10
(III)
3. Bedside glucose screening tests must be confirmed by
formal laboratory testing, although treatment should
begin immediately in infants with clinical signs.
Table 5 summarizes these recommendations.
Management of Documented Hypoglycemia (Table 6)
A. Infant with no clinical signs (absence of clinical
signs can only be determined by careful clinical review)
1. Continue breastfeeding (approximately every 1–2
hours) or feed 1–3 mL/kg (up to 5 mL/kg)
18
of ex-
pressed breastmilk or substitute nutrition (pasteurized
donor human milk, elemental formulas, partially hy-
drolyzed formulas, or routine formulas). Glucose wa-
ter is not suitable because of insufficient energy and
lack of protein. Recent reports of mothers with dia-
betes expressing and freezing colostrum prenatally
(beginning at 34–36 weeks of gestation) to have it
available after birth to avoid artificial feedings should
their infant become hypoglycemic are mixed in terms
of association with earlier births, and currently this
procedure is not widely recommended.
64–68
(III)
Table 5. General Management Recommendations
for All Term Infants
A. Early and exclusive breastfeeding meets the nutritional
and metabolic needs of healthy, term newborn infants.
1. Routine supplementation is unnecessary.
2. Initiate breastfeeding within 30–60 minutes of life and
continue on demand.
3. Facilitate skin-to-skin contact of mother and infant.
4. Feedings should be frequent, 10–12 times per 24 hours
in the first few days after birth.
B. Glucose screening is performed only on at-risk infants or
infants with clinical signs.
1. Routine monitoring of blood glucose in all term
newborns is unnecessary and may be harmful.
2. At-risk infants should be screened for hypoglycemia
with a frequency and duration related to the specific
risk factors of the individual infant.
3. Monitoring continues until normal, prefeed levels are
consistently obtained.
4. Bedside glucose screening tests must be confirmed by
formal laboratory testing.
Table 6. Management of Documented Hypoglycemia
A. Infant with no clinical signs
1. Continue breastfeeding (approximately every 1–2
hours) or feed 1–5 mL/kg of expressed breastmilk or
substitute nutrition.
2. Recheck blood glucose concentration before subse-
quent feedings until the value is acceptable and stable.
3. Avoid forced feedings (see above).
4. If the glucose level remains low despite feedings,
begin intravenous glucose therapy.
5. Breastfeeding may continue during intravenous glu-
cose therapy.
6. Carefully document response to treatment.
B. Infant with clinical signs or plasma glucose levels < 20–
25 mg/dL (< 1.1–1.4 mmol/L)
1. Initiate intravenous 10% glucose solution with a mini-
bolus.
2. Do not rely on oral or intragastric feeding to correct
extreme or clinically significant hypoglycemia.
3. The glucose concentration in infants who have had
clinical signs should be maintained at > 45 mg/dL
(> 2.5 mmol/L).
4. Adjust intravenous rate by blood glucose concentra-
tion.
5. Encourage frequent breastfeeding.
6. Monitor glucose concentrations before feedings while
weaning off the intravenous treatment until values
stabilize off intravenous fluids.
7. Carefully document response to treatment.
176 ABM PROTOCOL
2. Recheck blood glucose concentration before subsequent
feedings until the value is acceptable and stable (usu-
ally > 40 mg/dL [2.2 mmol/L]). If staff is unavailable to
check blood glucose and an infant has no clinical signs,
breastfeeding should never be unnecessarily delayed
while waiting for the blood glucose level to be checked.
3. If the infant is simply worn out and not otherwise ill,
nasogastric feeds of human milk can be initiated,
watching carefully for signs of intolerance or evidence
of significant underlying illness. If the neonate is too ill
to suck or enteral feedings are not tolerated, avoid
forced oral feedings (e.g., nasogastric tube) and instead
begin intravenous (IV) therapy (see below). Such an
infant is not normal and requires a careful examination
and evaluation in addition to more intensive therapy.
Term babies should not be given nasogastric feedings.
They are much more likely to fight and aspirate.
4. If the glucose level remains low despite feedings, be-
gin IV glucose therapy and adjust the IV rate by blood
glucose concentration. Avoid bolus doses of glucose
unless blood glucose is unrecordable or there are se-
vere clinical signs (e.g., seizures or coma). If a bolus
dose is given, use 2 mL/kg of glucose in 10% dextrose
preparation.
5. Breastfeeding should continue during IV glucose
therapy when the infant is interested and will suckle.
Gradually wean from the IV glucose as the serum
glucose level normalizes and feedings increase.
6. Carefully document physical examination, screening
values, laboratory confirmation, treatment, and chan-
ges in clinical condition (i.e., response to treatment).
7. The infant should not be discharged until reasonable
levels of blood glucose are maintained through a fast
of 3–4 hours. Monitoring must be recommenced if
there are adverse changes in feeding.
B. Infants with clinical signs or with plasma glucose
levels < 20–25 mg/dL ( < 1.1–1.4 mmol/L)
1. Initiate IV 10% glucose solution with a bolus of 2 mL/kg
and continuous IV treatment at 5–8 mg/kg/minute.
2. Do not rely on oral or intragastric feeding to correct
extreme or symptomatic hypoglycemia. Such an infant
most likely has an underlying condition and, in addi-
tion to IV glucose therapy, requires an immediate and
careful examination and evaluation.
3. The glucose concentration in infants with clinical signs
should be maintained at > 45 mg/dL (> 2.5 mmol/L).
4. Adjust the IV rate by blood glucose concentration.
5. Encourage frequent breastfeeding after initiation of IV
therapy.
6. Monitor glucose concentrations before feedings while
gradually weaning from the IV solution, until values
are stabilized off IV fluids.
7. Carefully document physical examination, screening
values, laboratory confirmation, treatment, and chan-
ges in clinical condition (i.e., response to treatment).
Supporting the Mother
Giving birth to an infant who develops hypoglycemia is of
concern to both the mother and family and thus may jeop-
ardize the establishment of breastfeeding. Mothers should be
explicitly reassured that there is nothing wrong with their
milk and that supplementation is usually temporary. Having
the mother hand-express or pump milk that is then fed to her
infant can overcome feelings of maternal inadequacy as well
as help establish a full milk supply. It is important for the
mother to provide stimulation to the breasts by manual or
mechanical expression with appropriate frequency (at least
eight times in 24 hours) until her baby is latching and suck-
ling well to protect her milk supply. Keeping the infant at
breast or returning the infant to the breast as soon as possible
is important. Skin-to-skin care is easily accomplished with an
IV line in place and may lessen the trauma of intervention,
while also providing physiologic thermoregulation, thus
contributing to metabolic homeostasis.
Recommendations for Future Research
1. Well-planned, well-controlled studies are needed that
look at plasma glucose concentrations, clinical signs,
and long-term sequelae to determine what levels of
blood glucose are the minimum safe levels.
2. The development and implementation of more reliable
bedside testing methods would increase the efficiency
of diagnosis and treatment of significant glucose ab-
normalities.
3. Studies to determine a clearer understanding of the
role of other glucose-sparing fuels and the methods to
measure them in a clinically meaningful way and time
frame are required to aid in understanding which ba-
bies are truly at risk of neurologic sequelae and thus
must be treated.
4. For those infants who do become hypoglycemic, re-
search into how much enteral glucose, and in what
form, is necessary to raise blood glucose to acceptable
levels is important for clinical management.
5. Randomized controlled studies of prenatal colostrum
expression and storage for mothers with infants at risk
of hypoglycemia are important to determine if this is a
practical and safe treatment modality.
Summary
Healthy term infants are programmed to make the tran-
sition from their intrauterine constant flow of nutrients to
their extrauterine intermittent nutrient intake without the
need for metabolic monitoring or interference with the
natural breastfeeding process. Homeostatic mechanisms
ensure adequate energy substrate is provided to the brain
and other organs, even when feedings are delayed. The
normal pattern of early, frequent, and exclusive breast-
feeding meets the needs of healthy term infants.
Routine screening and supplementation are not necessary
and may harm the normal establishment of breastfeeding.
Current evidence does not support a specific blood concen-
tration of glucose that correlates with signs or that can predict
permanent neurologic damage in any given infant. At-risk
infants should be screened, followed up as needed, and treated
with supplementation or IV glucose if there are clinical signs
or suggested thresholds are reached. Bedside screening is
helpful, but not always accurate, and should be confirmed with
laboratory glucose measurement. A single low glucose value is
not associated with long-term neurological abnormalities,
ABM PROTOCOL 177
provided the treating clinician can be assured that the baby was
entirely well up until the time of the low value. Hypoglycemic
encephalopathy and poor long-term outcome are extremely
unlikely in infants with no clinical signs and are more likely in
infants who manifest clinical signs and/or with persistent or
repeated episodes of severe hypoglycemia.
Acknowledgments
This work was supported in part by a grant from the Ma-
ternal and Child Health Bureau, U.S. Department of Health
and Human Services.
References
1. Adamkin DH, Committee on Fetus and Newborn. Postnatal
glucose homeostasis in late-preterm and term infants. Pe-
diatrics 2011;127:575–579.
2. Srinivasan G, Pildes RS, Cattamanchi G, et al. Plasma
glucose values in normal neonates: A new look. J Pediatr
1986;109:114–117.
3. Hawdon JM, Ward Platt MP, Aynsley-Green A. Patterns of
metabolic adaptation for preterm and term infants in the
first neonatal week. Arch Dis Child 1992;67(4 Spec No):
357–365.
4. Cornblath M, Reisner SH. Blood glucose in the neonate and
its clinical significance. N Engl J Med 1965;273:378–381.
5. Heck LJ, Erenberg A. Serum glucose levels in term neo-
nates during the first 48 hours of life. J Pediatr 1987;110:
119–122.
6. Hoseth E, Joergensen A, Ebbesen F, et al. Blood glucose
levels in a population of healthy, breast fed, term infants of
appropriate size for gestational age. Arch Dis Child Fetal
Neonatal Ed 2000;83:F117–F119.
7. Lucas A, Boyes S, Bloom SR, et al. Metabolic and endo-
crine responses to a milk feed in six-day-old term infants:
Differences between breast and cow’s milk formula feed-
ing. Acta Paediatr Scand 1981;70:195–200.
8. Edmond J, Auestad N, Robbins RA, et al. Ketone body
metabolism in the neonate: Development and the effect of
diet. Fed Proc 1985;44:2359–2364.
9. Yager JY, Heitjan DF, Towfighi J, Vannucci RC. Effect of
insulin-induced and fasting hypoglycemia on perinatal hyp-
oxic-ischemic brain damage. Pediatr Res 1992;31:138–142.
10. Cornblath M, Hawdon JM, Williams AF, et al. Con-
troversies regarding definition of neonatal hypoglycemia:
Suggested operational thresholds. Pediatrics 2000;105:
1141–1145.
11. Boluyt N, van Kempen A, Offringa M. Neurodevelopment
after neonatal hypoglycemia: A systematic review and design
of an optimal future study. Pediatrics 2006;117:2231–2243.
12. Koivisto M, Blanco-Sequeiros M, Krause U. Neonatal symp-
tomatic and asymptomatic hypoglycaemia: A follow-up study
of 151 children. Dev Med Child Neurol 1972;14:603–614.
13. Kinnala A, Rikalainen H, Lapinleimu H, et al. Cerebral
magnetic resonance imaging and ultrasonography findings
after neonatal hypoglycemia. Pediatrics 1999;103:724–729.
14. Dalgic N, Ergenekon E, Soysal S, et al. Transient neonatal
hypoglycemia—Long-term effects on neurodevelopmental
outcome. J Pediatr Endocrinol Metab 2002;15:319–324.
15. Burns C, Rutherford M, Boardman J, et al. Patterns of
cerebral injury and neurodevelopmental outcomes after
symptomatic neonatal hypoglycemia. Pediatrics 2008;122:
65–74.
16. Menni F, deLonlay P, Sevin C, et al. Neurologic outcomes
of 90 neonates and infants with persistent hyperinsulinemic
hypoglycemia. Pediatrics 2001;107:476–479.
17. Rozance PJ, Hay WW Jr. Describing hypoglycemia—
Definition or operational threshold? Early Hum Dev 2010;86:
275–280.
18. Williams AF. Hypoglycemia of the Newborn: Review of the
Literature. World Health Organization, Geneva, 1997.
19. Eidelman AI. Hypoglycemia and the breastfed neonate.
Pediatr Clin North Am 2001;48:377–387.
20. Hawdon JM, Ward Platt MP, Aynsley-Green A. Prevention
and management of neonatal hypoglycaemia. Arch Dis Child
Fetal Neonatal Ed 1994;70:F60–F64; discussion F65.
21. Wight N. Hypoglycemia in breastfed neonates.
Breastfeed
Med 2006;1:253–262.
22. Hawdon JM, Platt MP, Aynsley-Green A. Neonatal
hypoglycaemia—Blood glucose monitoring and baby
feeding. Midwifery 1993;9:3–6.
23. Hawdon J. Neonatal hypoglycemia: The consequences of
admission tothe special carenursery.Child Health 1993;(Feb):
48–51.
24. Kalhan S, Peter-Wohl S. Hypoglycemia: What is it for the
neonate? Am J Perinatol 2000;17:11–18.
25. Sinclair JC. Approaches to the definition of neonatal hy-
poglycemia. Acta Paediatr Jpn 1997;39(Suppl 1):S17–
S20.
26. Hay WW, Raju T, Higgens R, et al. Knowledge gaps and
research needs for understanding and treating neonatal
hypoglycemia: Workshop report from Eunice Kennedy
Shriver National Institute of Child Health and Human
Development. J Pediatr 2009;155:612–617.
27. Rozance PJ, Hay WW. Hypoglycemia in newborn infants:
Features associated with adverse outcomes. Biol Neonate
2006;90:74–86.
28. Aynsley-Green A. Glucose: A fuel for thought! J Paediatr
Child Health 1991;27:21–30.
29. Cornblath M, Schwartz R. Hypoglycemia in the neonate.
J Pediatr Endocrinol 1993;6:113–129.
30. Swenne I, Ewald U, Gustafsson J, et al. Inter-relationship
between serum concentrations of glucose, glucagon and
insulin during the first two days of life in healthy newborns.
Acta Paediatr 1994;83:915–919.
31. Durand R, Hodges S, LaRock S, et al. The effect of skin-to-
skin breast-feeding in the immediate recovery period on
newborn thermoregulation and blood glucose values. Neo-
natal Intensive Care 1997;10:23–29.
32. Cornblath M, Ichord R. Hypoglycemia in the neonate.
Semin Perinatol 2000;24:136–149.
33. Sexson WR. Incidence of neonatal hypoglycemia: A matter
of definition. J Pediatr 1984;105:149–150.
34. Harris DL, Weston PJ, Harding JE. Incidence of neonatal
hypoglycemia in babies identified as at risk. J Pediatr
2012;161:787–791.
35. Cole MD, Peevy K. Hypoglycemia in normal neonates ap-
propriate for gestational age. JPerinatol1994;14:118–120.
36. Stanley CA, Baker L. The causes of neonatal hypoglyce-
mia. N Engl J Med 1999;340:1200–1201.
37. Schwartz RP. Neonatal hypoglycemia: How low is too
low? J Pediatr 1997;131:171–173.
38. Alkalay A, Klein A, Nagel R, et al. Neonatal nonpersistent
hypoglycemia. Neonatal Intensive Care 2001;14:25–34.
39. McGowan JE. Commentary: Neonatal hypoglycemia—
Fifty years later, the questions remain the same. Neore-
views 2004;5:e363–e364.
178 ABM PROTOCOL
40. Alkalay AL, Sarnat HB, Flores-Sarnat L, et al. Population
meta-analysis of low plasma glucose thresholds in full-term
normal newborns. Am J Perinatol 2006;23:115–119.
41. Section on Breastfeeding. Breastfeeding and the use of
human milk. Pediatrics 2012;129:e827–e841.
42. Haninger NC, Farley CL. Screening for hypoglycemia in
healthy term neonates: Effects on breastfeeding. J Mid-
wifery Womens Health 2001;46:292–301.
43. National Childbirth Trust, United Kingdom. Hypoglycemia
of the newborn: Guidelines for the appropriate blood glu-
cose screening of breast-fed and bottle-fed babies in the
UK. Midwives 1997;110:248–249.
44. Ho HT, Yeung WK, Young BW. Evaluation of ‘‘point of
care’’ devices in the measurement of low blood glucose in
neonatal practice. Arch Dis Child Fetal Neonatal Ed
2004;89:F356–F359.
45. Altimier L, Roberts W. One Touch II hospital system for
neonates: Correlation with serum glucose values. Neonatal
Netw 1996;15(2):15–18.
46. Hussain K, Sharief N. The inaccuracy of venous and cap-
illary blood glucose measuurement using reagent strips in
the newborn period and the effect of haematocrit. Early
Hum Dev 2000;57:111–121.
47. Ellis M, Manandhar DS, Manandhar N, et al. Comparison
of two cotside methods for the detection of hypoglycaemia
among neonates in Nepal. Arch Dis Child Fetal Neonatal
Ed 1996;75:F122–F125.
48. Dahlberg M, Whitelaw A. Evaluation of HemoCue blood
glucose analyzer for the instant diagnosis of hypoglycaemia
in newborns. Scand J Clin Lab Invest 1997;57:719–724.
49. Sharief N, Hussein K. Comparison of two methods of
measurement of whole blood glucose in the neonatal pe-
riod. Acta Paediatr 1997;86:1246–1252.
50. Schlebusch H, Niesen M, Sorger M, et al. Blood glucose
determinations in newborns: Four instruments compared.
Pediatr Pathol Lab Med 1998;18:41–48.
51. Harris D, Weston P, Williams C, et al. Cot-side electro-
encephalography monitoring is not clinically useful in the
detection of mild neonatal hypoglycemia. J Pediatr
2011;159:755–760.
52. Harris D, Battin M, Weston P, et al. Continuous glucose
monitoring in newborn babies at risk of hypoglycemia. J
Pediatr 2010;157:198–202.
53. de Lonlay P, Giurgea I, Touati G, e tal. Neonatal hy-
poglycaemia: Aetiologies. Semin Neonatol 2004;9:49–58.
54. Cowett RM, Loughead JL. Neonatal glucose metabolism:
Differential diagnoses, evaluation, and treatment of hypo-
glycemia. Neonatal Netw 2002;21:9–19.
55. Sunehag AL, Haymond MW. Glucose extremes in newborn
infants. Clin Perinatol 2002;29:245–260.
56. Kalhan S, Parmimi P. Gluconeogenesis in the fetus and
neonate. Semin Perinatol 2000;24:94–106.
57. Hoops D, Roberts P, VanWinkle E, et al. Should routine
peripheral blood glucose testing be done for all newborns at
birth? MCN 2010;35:264–270.
58. Yager J. Hypoglycemic injury to the immature brain. Clin
Perinatol 2002;29:651–674.
59. Jain A, Aggarwal R, Jeeva Sankar M, et al. Hypoglycemia
in the newborn. Indian J Pediatr 2010;77:1137–1142.
60. Appendix A Task Force Ratings. Guide to Clinical Pre-
ventive Services: Report of the U.S. Preventive Services
Task Force, 2nd edition. www.ncbi.nlm.nih.gov/books/
NBK15430 (accessed March 28, 2014).
61. American Academy of Pediatrics, American College of
Obstetricians and Gynecologists. Guidelines for Perinatal
Care, 6th ed. American Academy of Pediatrics, Elk Grove
Village, IL, 2008.
62. World Health Oraganization, UNICEF. Protecting, Pro-
moting and Supporting Breast-Feeding: The Special Role
of Maternity Services, A Joint WHO/UNICEF Statement.
World Health Organization, Geneva, 1989.
63. Hawdon JM. Neonatal hypoglycemia: Are evidence-based
clinical guidelines achievable? Neoreviews 2014;15:e91–
e98.
64. Cox S G. Expr essing and stori ng col ostrum a ntenatally
for use in the newborn period. Breastfeed Rev 2006;14:
11–16.
65. Forster DA, McEgan K, Ford R, et al. Diabetes and ante-
natal milk expressing: A pilot project to inform the devel-
opment of a randomised controlled trial. Midwifery
2011;27:209–214.
66. Soltani H, Scott AM. Antenatal breast expression in women
with diabetes: Outcomes from a retrospective cohort study.
Int Breastfeed J 2012;7:18.
67. Chapman T, Pincombe J, Harris M. Antenatal breast ex-
pression: A critical review of the literature. Midwifery
2013;29:203–210.
68. Chapman T, Pincombe J, Harris M, et al. Antenatal breast
expression: Exploration and extent of teaching prac-
tices amongst International Board Certified Lactation
Consultant midwives across Australia. Women Birth 2013;
26:41–48.
ABM protocols expire 5 years from the date of publication.
Evidence-based revisions are made within 5 years or sooner
if there are significant changes in the evidence.
The Academy of Breastfeeding Medicine Protocol Committee
Kathleen A. Marinelli, MD, FABM, Chairperson
Maya Bunik, MD, MSPH, FABM, Co-Chairperson
Larry Noble MD, FABM, Translations Chairperson
Nancy Brent, MD
Amy E. Grawey, MD
Alison V. Holmes, MD, MPH, FABM
Ruth A. Lawrence, MD, FABM
Tomoko Seo, MD, FABM
Julie Scott Taylor, MD, MSc, FABM
For correspondence: abm@bfmed.org
ABM PROTOCOL 179
